A CASE REPORT ON SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (SOJIA) WITHOUT MULTIORGAN INVOLVEMENT

Authors

  • PATHAN AMANULLA KHAN Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.
  • SARAH NOUSHEEN BB Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.
  • ASFIYA BEGUM Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.
  • RAQSHAN JABEEN Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.
  • YOUSUF HUSSAIN Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.22159/ijs.2021.v9i1.39605

Keywords:

Systemic-onset juvenile idiopathic arthritis, Multiorgan, Nonsteroidal anti-inflammatory drugs, Methotrexate

Abstract

Systemic-onset juvenile idiopathic arthritis (SoJIA) is a rare form of juvenile idiopathic arthritis (JIA) which manifests as quotidian fevers and arthritis in one or more joints. Features include characteristic salmon pink-colored rash associated with lymphadenopathy, hepatosplenomegaly, and serositis. To the best of our knowledge, this is a rare form of JIA in India and very few cases without multiorgan involvement have been published in literature. The following case reports a 12-year-old male child who presented to the hospital with a history of spiking fevers and arthritis in the knees, ankle, and hip joints. Diagnosis of SoJIA was confirmed after subsequent laboratory investigations; treatment included long-term nonsteroidal anti-inflammatory drugs, and methotrexate. However, due to increased cost of medicines and no guaranteed “cure” for the disease, the present patient switched from allopathic to homeopathic medicines. He still experiences frequent flare-ups associated with the disease, during which aceclofenac is taken for symptom relief. This case also highlights the importance of a “cure” for diseases rather than “symptom-oriented” treatment measures. When a cure is not guaranteed, patients may transition to inexpensive alternate therapies portraying limited efficacy. Further research in the field of rheumatology, specifically for rare diseases, is warranted.

Author Biography

SARAH NOUSHEEN BB, Department of Pharmacy Practice, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.

Address for correspondence:

B. B. Sarah Nousheen

Department of Pharmacy Practice

Anwarul Uloom College of Pharmacy,

Hyderabad – 500 001, Telangana, India.

Email: sarahnousheen@gmail.com

References

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.

Viswanathakumar HM, Kumar GV. Study of clinical spectrum of juvenile idiopathic arthritis in children in a tertiary referral hospital. Curr Pediatr Res 2014;18:21-5.

Seth V, Kabra SK, Semwal OP, Jain Y. Clinico-immunological profile in juvenile rheumatoid arthritis-an Indian experience. Indian J Pediatr 1996;63:293-300.

Suni KA, Ali A, Lal AA, Kailas L. Clinico-immunological profile of juvenile idiopathic arthritis in children attending SAT hospital, Thiruvananthapuram. Acad Med J India 2015;3:99-105.

Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania systemic onset juvenile arthritis registry (PASOJAR). J Rheumatol 2008;35:343-8.

Nandi M, Ganguli SK, Mondal R, Ghosh A. Clinico-serological profile of juvenile idiopathic arthritis. Indian Pediatr 2009;46:640-1.

Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-60.

Cimaz R, Scheven AV, Hofer M. Systemic-onset juvenile idiopathic arthritis: The changing life of a rare disease. Swiss Med Wkly 2012;142:w13582.

Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245-71.

Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: A retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6.

Phelan JD, Thompson SD, Glass DN. Susceptibility to JRA/JIA: Complementing general autoimmune and arthritis traits. Genes Immun 2006;7:1-10.

Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65 Suppl 1:S11-5.

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur) 2010;5:286-91.

Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008;47:555-6.

Paul S, Das AP, Bhattacharjee S. Rheumatoid arthritis: Molecular basis and cures from nature. Int J Pharm Pharm Sci 2015;7:30-9.

Gupta MK, Shrivastava AK, Chauhan AP, Gaur DS, Mishra KK, Sharma S. Comparative study of the shiva guggulu and simhanada guggulu in the management of amavata (rheumatoid arthritis). Int J Appl Pharm 2016;8:5-12.

Wee AS, Said MS, Redzuan AB. Medication adherence status among rheumatoid arthritis patients. Int J Pharm Pharm Sci 2016;8:317-21.

Published

01-01-2021

How to Cite

KHAN, P. A., NOUSHEEN BB, S., BEGUM, A., JABEEN, R., & HUSSAIN, Y. (2021). A CASE REPORT ON SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (SOJIA) WITHOUT MULTIORGAN INVOLVEMENT. Innovare Journal of Sciences, 9(1), 4–6. https://doi.org/10.22159/ijs.2021.v9i1.39605

Issue

Section

Case Study(s)